International Rhinologic Society Rhinology 0300-0729 2026 10 17 Pocket guide Biologics in upper and lower airway diseases 2026 by EUFOREA EN G. VerstappenLaboratory of Allergy and Clinical Immunology Research Unit, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium Department of Otorhinolaryngology-Head and Neck Surgery, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Health Campus, Brussels, Belgium X. Bertels The European Forum for Research and Education in Allergy and Airway Diseases Scientific Expert Team Members, Brussels, Belgium R.O. Al-LehebiDepartment of pulmonology, King Fahad Medical City, Riyadh, Saudi Arabia Alfaisal University, Riyadh, Saudi Arabia B.M. Alim Division of Otolaryngology, Prince Mohammed Bin Abdulaziz Hospital, Medina, Saudi Arabia N.H. AlotaibiAlfaisal University, Riyadh, Saudi Arabia Otolaryngology-Head and Neck Surgery Department, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia S. AlsalehDepartment of Otolaryngology-Head and Neck Surgery, King Saud University, Riyadh, Saudi Arabia Security Forces Hospitals Program, General Directorate of Medical Services, Ministry of Interior, Riyadh, Saudi Arabia V. Backer Department of Otorhinolaryngology, Head and Neck Surgery, and Audiology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark M. Bernal-Sprekelsen Hospital Clinic, Barcelona, University of Barcelona, Spain B.S. Bleier Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, United Kingdom Y. Chan Department of Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada D.M. ContiLaboratory of Allergy and Clinical Immunology Research Unit, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium Escuela de Doctorado UAM, Centro de Estudios de Posgrado, Universidad Autónoma de Madrid, Calle Francisco Tomás y Valiente nº 2. Ciudad Universitaria de Cantoblanco, Madrid, Spain M.E. Cornet Alrijne Ziekenhuis, Leiderdorp, the Netherlands E. de Corso Department of Medicine and Surgery, Section of Otorhinolaryngology, University of Perugia, Perugia, Italy P. Gevaert Department of Otorhinolaryngology, Laboratory of Upper Airways Research, University of Ghent, Ghent, Belgium J HagemannClinic for Ear, Nose and Throat Medicine, Mainz University Medical Center, Mainz, Germany Center for Rhinology and Allergology, Wiesbaden, Germany J. Han Department of Otolaryngology and Head and Neck Surgery, Eastern Virginia Medical School, Norfolk, VA, United States C.H. Hopkins Department of Rhinology and Skull Base Surgery, Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom M. Jeseňák Institute of Clinical Immunology and Medical Genetics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Martin, Slovakia E. KhalevaHuman Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom S. Lau Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany S.E. Lee Division of Rhinology and Skull Base Surgery, Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, MD, United States V.J. LundRoyal National Ear, Nose and Eastman Dental Hospital, London, United Kingdom Ear Institute, University College London Hospitals, United Kingdom A.T. Peters Department of Medicine, Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States C. Pipolo Otolaryngology Unit, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Italy K.F Rabe LungenClinic Grosshansdorf and Christian-Albrechts University (members of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Kiel, Germany G. ScaddingDepartment of Allergy and Rhinology, Royal National ENT Hospital, London, United Kingdom Division of Immunity and Infection, University College, London, United Kingdom S. Schneider Department of Otorhinolaryngology, Head and Neck Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria B.A. Senior Department of Otolaryngology/Head and Neck Surgery, University of North Carolina, Chapel Hill, NC, United States P.K. Smith Griffith University, School of Medicine, Southport, Queensland, Australia M.E. Wechsler Department of Medicine, National Jewish Health, Denver, CO, United States W.J. Fokkens Amsterdam UMC, University of Amsterdam, Department of Otorhinolaryngology, Amsterdam, the Netherlands P.W. HellingsLaboratory of Allergy and Clinical Immunology Research Unit, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Belgium Letter 3642 10.4193/Rhin26.419 Over the past decade, biologic therapies targeting key inflammatory pathways have fundamentally transformed the treatment landscape for patients with chronic inflammatory airway diseases. These therapies are now widely approved worldwide and increasingly implemented in routine clinical practice. Real-world studies confirm their effectiveness beyond controlled clinical trial settings and highlight biologics as a major therapeutic advance for severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and eosinophilic chronic obstructive pulmonary disease (COPD). Biologics have been shown to significantly improve disease control and potentially enable the achievement of new treatment goals, including clinical and complete remission.